Bendamustine news

All news on Bendamustine (also known as Bendamustine hydrochloride, Treanda, Levact, and Ribomustin): plants, production capacities, investments and involved companies.

17 June 2026

Genentech seeks FDA approval for Lunsumio VELO plus Polivy in relapsed/refractory LBCL

sBLA accepted for subcutaneous bispecific + ADC combo in relapsed/refractory large B‑cell lymphoma; FDA decision expected Feb 9, 2027.
20 April 2026

FDA Accepts Genentech sBLA for Gazyva in SLE

FDA accepted sBLA for an anti‑CD20 in SLE after Phase III ALLEGORY: SRI‑4 responders 76.7% vs 53.5%, higher remission, fewer flares and steroid reduction; decision due Dec 2026.

Who will be producing Bendamustine in the future?

Find out with chemXplore Alpha

Learn more